补体因子H的转化性小型综述系列：与补体因子H异常相关的肾脏疾病的治疗：非典型溶血尿毒综合征和膜增生性肾小球肾炎
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.
作者信息
Noris M, Remuzzi G
机构信息
Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi - Ranica (BG), Italy.
出版信息
Clin Exp Immunol. 2008 Feb;151(2):199-209. doi: 10.1111/j.1365-2249.2007.03558.x. Epub 2007 Dec 7.
Abstract
Genetic and acquired abnormalities in complement factor H (CFH) have been associated with two different human renal diseases: haemolytic uraemic syndrome and membrano proliferative glomerulonephritis. The new genetic and pathogenetic findings in these diseases and their clinical implications for the management and cure of patients are reviewed in this paper.
摘要
补体因子H（CFH）的遗传和后天异常与两种不同的人类肾脏疾病相关：溶血性尿毒症综合征和膜增生性肾小球肾炎。本文综述了这些疾病的新遗传和发病机制研究结果及其对患者管理和治疗的临床意义。
相似文献
1
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.补体因子H的转化性小型综述系列：与补体因子H异常相关的肾脏疾病的治疗：非典型溶血尿毒综合征和膜增生性肾小球肾炎
Clin Exp Immunol. 2008 Feb;151(2):199-209. doi: 10.1111/j.1365-2249.2007.03558.x. Epub 2007 Dec 7.
2
Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.膜增生性肾小球肾炎、非典型溶血尿毒症综合征和一种新的补体因子 H 突变：病例报告。
Pediatr Nephrol. 2012 Oct;27(10):1995-9. doi: 10.1007/s00467-012-2210-0. Epub 2012 Jun 5.
3
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.补体因子H相关的转化性小型综述系列：与补体因子H相关的肾脏疾病——来自人类和动物的新见解
Clin Exp Immunol. 2008 Feb;151(2):210-30. doi: 10.1111/j.1365-2249.2007.03574.x.
4
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.补体因子H的转化性小型综述系列：人类补体因子H的遗传学与疾病关联
Clin Exp Immunol. 2008 Jan;151(1):1-13. doi: 10.1111/j.1365-2249.2007.03552.x.
5
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.伴有孤立性C3沉积的原发性肾小球肾炎：一种与溶血尿毒综合征具有共同遗传风险因素的新实体。
J Med Genet. 2007 Mar;44(3):193-9. doi: 10.1136/jmg.2006.045328. Epub 2006 Oct 3.
6
Complement factor H and haemolytic uraemic syndrome.补体因子H与溶血尿毒综合征
Lancet. 2002 Mar 2;359(9308):801-2. doi: 10.1016/S0140-6736(02)07866-2.
7
Complement in glomerular injury.补体在肾小球损伤中的作用
Semin Immunopathol. 2007 Nov;29(4):375-84. doi: 10.1007/s00281-007-0090-3. Epub 2007 Sep 28.
8
Factor H family proteins and human diseases.补体因子H家族蛋白与人类疾病。
Trends Immunol. 2008 Aug;29(8):380-7. doi: 10.1016/j.it.2008.04.008. Epub 2008 Jul 2.
9
Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMD.补体H因子的基因型-表型相关性：来自非典型溶血尿毒综合征、II型膜增生性肾小球肾炎和年龄相关性黄斑变性的经验教训。
Kidney Int. 2006 Jul;70(1):12-3. doi: 10.1038/sj.ki.5001612.
10
The spectrum of phenotypes caused by variants in the CFH gene.CFH基因变异导致的表型谱。
Mol Immunol. 2009 May;46(8-9):1573-94. doi: 10.1016/j.molimm.2009.02.013. Epub 2009 Mar 17.
引用本文的文献
1
Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome.个体化治疗非典型溶血尿毒综合征患者。
Clin Med (Lond). 2024 Nov;24(6):100250. doi: 10.1016/j.clinme.2024.100250. Epub 2024 Oct 4.
2
Proof of concept of a new plasma complement Factor H from waste plasma fraction.新型血浆补体因子 H 从废血浆级分的概念验证。
Front Immunol. 2024 Jun 6;15:1334151. doi: 10.3389/fimmu.2024.1334151. eCollection 2024.
3
Gliosis-dependent expression of complement factor H truncated variants attenuates retinal neurodegeneration following ischemic injury.胶质细胞依赖性补体因子 H 截断变体的表达减轻缺血性损伤后视网膜神经退行性变。
J Neuroinflammation. 2024 Feb 22;21(1):56. doi: 10.1186/s12974-024-03045-3.
4
A case of unexpected diagnosis of fibronectin glomerulopathy with histological features of membranoproliferative glomerulonephritis.一例以膜增生性肾小球肾炎组织学特征为表现的纤维连接蛋白肾小球病的意外诊断。
BMC Nephrol. 2024 Jan 22;25(1):25. doi: 10.1186/s12882-024-03456-7.
5
Calcitriol Reduces the Inflammation, Endothelial Damage and Oxidative Stress in AKI Caused by Cisplatin.骨化三醇可降低顺铂所致 AKI 的炎症、内皮损伤和氧化应激。
Int J Mol Sci. 2022 Dec 14;23(24):15877. doi: 10.3390/ijms232415877.
6
Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling.通过数学建模对因子 H 介导的自身与非自身识别进行定量分析。
Front Immunol. 2020 Sep 2;11:1911. doi: 10.3389/fimmu.2020.01911. eCollection 2020.
7
Review: Complement and its regulatory proteins in kidney diseases.综述：肾脏疾病中的补体及其调节蛋白。
Nephrology (Carlton). 2010 Oct;15(7):663-75. doi: 10.1111/j.1440-1797.2010.01373.x.
8
Clinical practice. Today's understanding of the haemolytic uraemic syndrome.临床实践。对溶血尿毒综合征的现代认识。
Eur J Pediatr. 2010 Jan;169(1):7-13. doi: 10.1007/s00431-009-1039-4. Epub 2009 Aug 26.
9
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.补体抑制剂依库珠单抗治疗非典型溶血性尿毒症综合征
Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25.
10
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.补体片段C3b-因子H的结构及其对补体调节因子宿主保护作用的影响
Nat Immunol. 2009 Jul;10(7):728-33. doi: 10.1038/ni.1755. Epub 2009 Jun 7.
本文引用的文献
1
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.非志贺毒素相关性溶血尿毒综合征患者肾移植的结局：遗传背景的预后意义
Clin J Am Soc Nephrol. 2006 Jan;1(1):88-99. doi: 10.2215/CJN.00050505. Epub 2005 Nov 2.
2
New approaches to the treatment of dense deposit disease.治疗致密物沉积病的新方法。
J Am Soc Nephrol. 2007 Sep;18(9):2447-56. doi: 10.1681/ASN.2007030356. Epub 2007 Aug 5.
3
A descriptive study of individuals with membranoproliferative glomerulonephritis.一项关于膜增生性肾小球肾炎患者的描述性研究。
Nephrol Nurs J. 2007 May-Jun;34(3):295-302; quiz 303.
4
Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus.使用他克莫司使Ⅰ型膜增生性肾小球肾炎缓解。
Pediatr Nephrol. 2007 Oct;22(10):1787-91. doi: 10.1007/s00467-007-0523-1. Epub 2007 Jul 3.
5
Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.霉酚酸酯治疗难治性肾小球病
Nephrology (Carlton). 2007 Jun;12(3):285-8. doi: 10.1111/j.1440-1797.2006.00763.x.
6
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.抗因子H自身抗体在溶血尿毒综合征中阻断因子H的C端识别功能。
Blood. 2007 Sep 1;110(5):1516-8. doi: 10.1182/blood-2007-02-071472. Epub 2007 May 10.
7
Dense deposit disease: new insights.致密沉积物病：新见解
Curr Opin Nephrol Hypertens. 2007 May;16(3):204-12. doi: 10.1097/MNH.0b013e3280bdc0f4.
8
Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate.新生儿完全性补体因子H缺乏相关的非典型溶血尿毒综合征
Pediatr Nephrol. 2007 Jun;22(6):874-80. doi: 10.1007/s00467-007-0438-x. Epub 2007 Feb 13.
9
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.补体因子B的功能获得性突变与非典型溶血性尿毒症综合征相关。
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):240-5. doi: 10.1073/pnas.0603420103. Epub 2006 Dec 20.
10
A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome.补体I因子（IF）的错义突变易导致非典型溶血尿毒综合征。
Pediatr Nephrol. 2007 Mar;22(3):371-5. doi: 10.1007/s00467-006-0320-2. Epub 2006 Nov 15.
Zotero 插件